Introduction {#s1}
============

Cancer genetics and epigenetics are closely linked in driving the cancer phenotype ([@B2]). The vast majority of human cancers emerge from a gradual accumulation of somatic alterations and epigenetic abnormalities, which together lead to the malignant growth ([@B16]). Epigenetic changes can further enable tumor cells to escape from host immune surveillance and various treatments ([@B36]). Epigenetic abnormalities are usually observed as disrupted DNA methylation patterns ([@B6]), abnormal histone post translational modifications ([@B26]), and aberrant changes in chromatin organization ([@B1]). How to identify epigenetic modification patterns that lead to the corresponding dysregulation in diverse cancers has become a critical research issue of cancer studies ([@B7]; [@B18]).

Great advancements have been made in delineating the underlying mechanisms of human cancers ([@B21]; [@B23]). Extensive research has centered on the genetic aspect of cancers, such as how mutational activation and inactivation of cancer genes influence the cellular pathways ([@B31]; [@B32]). Recently, an increasing emphasis of drug discovery efforts has been targeting on the cancer epigenome ([@B10]). Many epigenome mapping projects have been gradually founded. The Cancer Genome Atlas Network (TCGA), BLUEPRINT, and the International Cancer Genome Consortium (ICGC) define the genome-wide distribution of epigenetic marks in many normal and cancerous tissues ([@B4]; [@B20]; [@B33]). Given the genome-wide distribution of epigenetic modifications of different cancers, it is urgent to decipher common epigenetic patterns across cancers and to understand the underlying mechanisms of tumorigenesis. Key epigenomic similarities shared by different cancer types would present an important opportunity to design effective cancer treatment strategies among cancers regardless of tissue or organ and enable the extension of effective treatments from one cancer type to another ([@B17]; [@B11]).

To detect significant epigenetic patterns, existing computational methods mainly focus on identifying combinatorial states of different epigenetic marks. Specifically, CoSBI captures diverse histone modification patterns based on the correlations of different histone signals ([@B29]). ChromHMM and HiHMM both apply a HMM model to annotate genomic sequences by the co-occurrence of multiple epigenetic marks ([@B9]; [@B27]). RFECS is developed mainly based on random forests ([@B25]). IDEAS is able to jointly characterize epigenetic landscapes in many cell types and detect differential regulatory regions ([@B37]). These methods have successfully identified the combinatorial epigenetic pattern in specific cell type. However, the relations among different cancer types still need to be investigated. Because DNA methylation in cancers has been addressed elsewhere ([@B19]; [@B34]), here we only focus on the critical covalent histone modifications that are altered in various cancers, particularly the well-studied acetylation and methylation modifications.

In this paper, we proposed a tri-clustering approach, named TriPCE, for integrative pan-cancer epigenomic analysis. The method TriPCE adopts a tri-clustering strategy to identify the coherent patterns of various epigenetic modifications across different cancer types. We applied TriPCE to investigate six critical epigenetic marks among seven cancer types, and identified significant pan-cancer epigenetic modification patterns. The results reveal that there exists consistent epigenetic modification tendency among these cancer types. Meanwhile, the gene function analysis demonstrates that these associated genes are strongly relevant with the cancer cellular pathway.

Materials and Methods {#s2}
=====================

Datasets {#s2_1}
--------

To detect epigenetic similarities among different cancers, we analyzed the epigenome maps of seven cancer types, including A549, K562, HepG2, HCT116, Hela-S3, multiple myeloma-Cell Line, and sporadic Burkitt lymphoma-Cell Line. For the epigenetic marks, we first filtered out those marks that are not included in these seven cancer types, and then focused on six widely studied ones, including H3K4me1, H3K4me3, H3K9me3, H3K27ac, H3K27me3, and H3K36me3. Meanwhile, the RNA expression profiles of these cancers were also collected. Totally, we obtained 42 epigenome maps and 7 RNA expression profiles for these cancers. The datasets were downloaded from the website of NIH Roadmap Epigenome Project.

General Scheme of the TriPCE Approach {#s2_2}
-------------------------------------

We developed a tri-clustering approach TriPCE to dissect the pan-cancer epigenetic pattern. The method not only explicitly detects combinatorial states of various epigenetic marks in different genomic segments, but also mines similar epigenetic patterns across different cancer types. The proposed TriPCE model has three key components, as shown in [**Figure 1**](#f1){ref-type="fig"}. Firstly, preprocess the modification data of various epigenetic marks in different cancer types. Secondly, identify bi-Clusters based on FP-growth algorithm for each epigenetic mark. Thirdly, mine tri-Clusters with coherent epigenetic modification patterns across different cancer types.

![The flowchart of the proposed TriPCE approach. **(A)** Preprocessing the epigenetic modification data of different cancer types. **(B)** For each epigenetic mark, identifying bi-Clusters based on the FP-growth algorithm. **(C)** Mining tri-Clusters with coherent epigenetic modification patterns across different cancer types.](fgene-10-01298-g001){#f1}

**Step 1.** Preprocess the epigenetic modification data of different cancer types. Firstly, the genome was divided into consecutive genomic segments, with a typical segment size of 200 bps ([@B12]). For each epigenetic modification map, we computed the summary tag count of every segment. Then, each segment is associated with the intensities of a set of epigenetic modifications in each cancer type. To deduce the impact of the noise resulting from spurious tag counts in the ChIP-seq experiments, raw sequence read counts of each epigenetic modification were further normalized by the total number of reads followed by arcsine transformation ([@B24]). Finally, according to the genome annotation data, the epigenetic distribution in the promoter regions was extracted.

After the preprocessing step, we gained six epigenetic profiles of seven cancer types along the promoter regions. Let *G* = {*ɡ* ~1~, *ɡ* ~2~,..., *ɡ~n~*} be a set of *n* genes, let *T* = {*t* ~1~, *t* ~2~,..., *t* ~7~} be the investigated seven cancer types and let *E* = {*e* ~1~, *e* ~2~,..., *e* ~6~} be the six epigenetic marks. For each epigenetic mark, the epigenetic profiles of different cancer types in the promoter regions of these genes are organized as a matrix $D_{k} = T \times G = \left\{ t_{i,j}^{k} \right\}$ (with *i* ∈\[1,2...,7\], *j* ∈\[1,2..., *n*\], *k* ∈\[1,2...,6\]), where rows correspond to the cancer types, and columns correspond to those genes, respectively. Each entry $t_{i,j}^{k}$ is a vector representing the epigenetic profile of *e~k~* in the *i*th cancer along the promoter region of gene *j*.

**Step 2.** Identify bi-clusters based on FP-growth algorithm for each epigenetic mark. Given the preprocessed and reorganized epigenetic modification data matrix of each epigenetic mark, we first computed the Pearson correlation coefficients between the epigenetic profiles of any two cancer types at every promoter region, and then obtained a correlation coefficient matrix.

Specifically, for the promoter region *ɡ~i~,* we computed the Pearson correlation coefficients among the epigenetic modification distribution vectors of any different cancer types. If the calculated correlation coefficient is higher than a given threshold, the epigenetic modification trend in these two cancer types is regarded as coherent in this promoter region. Then, we added this cancer type to the corresponding itemset, which contains all the cancer types exhibiting similar epigenetic patterns in this region. Based on extensive experimental comparison, when the correlation coefficient threshold is set as 0.7, the identified epigenetic patterns are obviously coherent. For each epigenetic mark, we respectively constructed the corresponding similar itemsets for all promoter regions.

Based on the resulted itemset, we further identified the significant coherent epigenetic patterns using FP-growth algorithm ([@B13]). FP-growth algorithm is a data mining method that was originally developed for frequent itemset mining in market basket analysis. Here, we adopted the FP-tree model to represent in a compact way all the cancer types with similar epigenetic patterns in different promoter regions. Then, it can be used to mine potential frequent itemsets and filter out most of the unrelated data. In this context, a typical frequent itemset represents a group of cancer types that share similar epigenetic patterns in abundant promoter regions. To gain the significant epigenetic states, we set the minimum support of genes as 10% of the investigated genes. For each frequent itemset, we then inversely identified the corresponding gene set and gained the bi-Cluster. The resulted bi-Cluster is in the form ("genomic regions," "cancer types"), representing the cancer types exhibit similar epigenetic patterns in these genes. Similarly, we obtained the corresponding bi-Cluster sets for all investigated epigenetic marks.

**Step 3.** Mine tri-Clusters with coherent epigenetic modification patterns across different cancer types. After obtaining the bi-Cluster sets for each epigenetic mark, we further mined the tri-Clusters. By enumerating the maximum subsets of different epigenetic marks, we obtained the tri-Clusters. In detail, we respectively computed the intersection of the bi-Cluster sets from two epigenetic marks *e~k~* and *e~l~*, which are kept with the epigenetic marks to get possible tri-Clusters. Further, by filtering out the candidates with the support lower than the predefined minimum support, we obtained the significant tri-Clusters. Iteratively, we continued the process with another epigenetic mark until all the epigenetic marks were analyzed. We tried all such paths and kept the maximal tri-Clusters only. Each tri-Cluster is represented as ("genomic regions," "cancer types," "epigenetic marks"), listing a gene set with similar trend of epigenetic modifications in different cancer types. The resulted tri-Clusters indicate that the conserved epigenetic signatures in these genomic regions are shared by multiple cancer types.

Functional Analysis of the Genes {#s2_3}
--------------------------------

From the identified tri-Clusters, we can obtain the gene sets associated with specific coherent epigenetic patterns. To investigate the potential functions of these genes, we performed the gene ontology (GO) enrichment analysis and pathway enrichment analysis *via* DAVID bioinformatics resources ([@B14]). The significant enrichment lists were obtained with P-value \< 0.005.

Results {#s3}
=======

Identifying Similar Epigenetic Patterns Across Different Cancer Types {#s3_1}
---------------------------------------------------------------------

We developed a tri-clustering approach, TriPCE, to capture similar epigenetic patterns among different cancer types. TriPCE was applied to the genome-wide epigenetic modification maps of seven cancer types, including A549, K562, HepG2, HCT116, Hela-S3, multiple myeloma-Cell Line, and sporadic Burkitt lymphoma-Cell Line. For each epigenetic mark, TriPCE first groups the promoter regions based on the epigenetic modification profiles among different cancer types. [**Figure 2**](#f2){ref-type="fig"} shows a typical bi-Cluster of epigenetic mark H3K4me1, which contains abundant genes with similar modification pattern in four cancer types, including Hela-S3, HepG2, K562, and A549. From this figure, we observe that the epigenetic profiles of these genes are similar in these cancer types. Then, the epigenetic profile shared by a cluster of promoter regions in multiple cancer types is considered to be an epigenetic pattern. Meanwhile, different cancer types share similar epigenetic patterns. This result is consistent with previous finding that H3K9me3/me2 and H3K36me3/me2 frequently observed in breast cancer ([@B22]), esophageal cancer ([@B35]), MALT lymphoma ([@B30]), and lung sarcomatoid carcinoma ([@B15]). Based on the identified bi-Clusters of these investigated epigenetic marks, we noted that cancers (HepG2 and HCT116) are clustered together and share a larger number of epigenetic marks, implying that they share more similar epigenetic regulation mechanisms.

![The profiles of epigenetic mark H3K4me3 in a typical bi-Cluster exhibit a similar pattern in four cancer types, including Hela-S3, HepG2, K562 and A549.](fgene-10-01298-g002){#f2}

To identify the significant modification patterns, we set the minimal support of genes as 10% of the investigated genes. With diverse correlation coefficient thresholds, we respectively gained different numbers of bi-Clusters for epigenetic marks H3K4me1, H3K4me3, H3K9me3, H3K27me3, H3K36me3, and H3K27ac, among these cancer types, as shown in [**Figure 3**](#f3){ref-type="fig"}. The comparison indicates that the similarities of these epigenetic marks are quite different. Under different threshold settings, the epigenetic mark H3K4me3 has a relatively small number of bi-Clusters, indicating that its profiles are less conserved and exhibit more variable patterns among these cancer types than other epigenetic marks. On the contrary, there are more similar epigenetic patterns of H3K4me1 and H3K27me3 among different cancer types ([@B3]). The plasticity of epigenome depends on diverse environmental factors. Thus, it is not surprising that epigenotypes contribute to developmental human disorders and adult diseases ([@B5]). As the minimal support threshold slightly affects the trend among different epigenetic marks, we chose the bi-Clusters with threshold 0.7 for further analysis.

![The numbers of bi-Clusters with varied similarity thresholds for different epigenetic marks.](fgene-10-01298-g003){#f3}

Identifying Coherent Patterns Among Different Epigenetic Marks {#s3_2}
--------------------------------------------------------------

From the above results, we notice that there are obvious differences among the investigated epigenetic modifications. To identify the conserved epigenetic states and explore the similar patterns of these epigenetic modifications, we further clustered these epigenetic marks based on the detected bi-Clusters. By systematically computing the intersection of the bi-Cluster sets from different epigenetic marks, we kept the tri-Clusters with the support higher than the predefined minimum support. The identified tri-Clusters are represented as triples ("genomic regions," "cancer types," "epigenetic marks"). Each tri-Cluster represents that the promoter region of these genes exhibits similar epigenetic modification patterns in the related cancer types.

Applying TriPCE to the data set, we initially obtained 175 significant tri-Clusters. [**Figure 4**](#f4){ref-type="fig"} shows the information of 15 typical clusters, including the epigenetic marks, the cancer types, and the supports of these tri-Clusters. The results indicate that specific genomic regions indeed share combinatorial epigenetic patterns across different cancer types. For example, the changing pattern of epigenetic modifications (H3K4me3, H3K9me3, H3K27me3, and H3K36me3) are shared by a large number of genes in cancer types A549, HepG2, and K562. On the contrary, some epigenetic modification patterns are only coherent in certain cancer types. Among these resulted clusters, we observe that the similar patterns of H3K36me3, H3K27ac, and H3kK27me3 exist in fewer cancer types, such as HepG2 and sporadic Burkitt lymphoma-Cell Line. Notably, these identified tri-Clusters reveal more information about the epigenetic patterns among these cancer types.

![Typical epigenetic tri-Clusters. **(A)** The epigenetic marks (column) in each cluster (row). **(B)** The cancer types (column) in each cluster (row). Fold enrichment was calculated as the ratio between the number of genes in the tri-Cluster to that of all genes.](fgene-10-01298-g004){#f4}

Analyzing the Potential Roles of Associated Genes {#s3_3}
-------------------------------------------------

Based on the detected tri-Clusters, we further obtained those gene sets that exhibit coherent epigenetic patterns in different cancer types. Previous studies have shown that the modification intensities are significantly distinct between high-expression gene promoters and low-expression gene promoters, which suggests that these chromatin components have significant effect on gene regulation ([@B28]). To investigate the potential functions of those genes in the cellular control pathways, we performed a systematic GO enrichment analysis using DAVID tools (<https://david.ncifcrf.gov/>). Then, for the associated gene sets in the identified tri-Clusters, we respectively summarized the key biological processes and pathways that they are involved in.

Overall, we found that those genes enriched in tri-Clusters exhibit an enrichment for cancer-related functions. [**Table 1**](#T1){ref-type="table"} lists the significant GO terms of a typical tri-Cluster (P-value \< 0.005). In this tri-Cluster, the genes exhibit coherent modification patterns on epigenetic marks (H3K4me1, H3K4me3, H3K9me3, H3K27ac, and H3K27me3) in cancer types (HeLa-S3, HepG2, multiple myeloma-Cell Line, and sporadic Burkitt lymphoma-Cell Line). In the table, terms "positive regulation of cell proliferation" and "negative regulation of apoptotic process" are enriched in these gene sets. This result implies that the identified genes in this tri-Cluster are essential for cell proliferation and apoptotic process, which has been reported to be related to cancer development by previous researches ([@B8]). Meanwhile, the term "positive regulation of gene expression" is also enriched in the gene set, further indicating that these genes might perform important regulation roles in these cancers.

###### 

Functional enrichment of genes in the identified tri-Clusters.

  Term type   Term name                                                     P-value    Term type   Term name                                P-value
  ----------- ------------------------------------------------------------- ---------- ----------- ---------------------------------------- ----------
  BP          Positive regulation of cell proliferation                     2.84E-06   MF          Protein binding                          1.10E-12
  BP          Translational initiation                                      1.18E-05   MF          Poly(A) RNA binding                      3.90E-10
  BP          mRNA processing                                               2.72E-05   MF          RNA binding                              2.13E-05
  BP          Cell division                                                 4.08E-05   MF          Glutathione binding                      7.85E-04
  BP          rRNA processing                                               2.70E-04   MF          Enzyme regulator activity                4.02E-03
  BP          RNA splicing                                                  4.04E-04   MF          Nucleosomal DNA binding                  4.25E-03
  BP          Positive regulation of gene expression, epigenetic            9.41E-04   MF          Translation initiation factor activity   4.30E-03
  BP          Protein targeting to Golgi                                    8.87E-05   MF          Glutathione transferase activity         8.00E-03
  BP          Nitrobenzene metabolic process                                1.14E-04   MF          Protein binding, bridging                4.33E-03
  BP          Xenobiotic catabolic process                                  1.13E-03   MF          ATP binding                              4.57E-03
  BP          mRNA splicing, *via* spliceosome                              1.14E-03   CC          Nucleoplasm                              6.18E-13
  BP          Sister chromatid cohesion                                     2.13E-03   CC          Cytosol                                  3.96E-07
  BP          SRP-dependent cotranslational protein targeting to membrane   1.06E-03   CC          Membrane                                 7.68E-06
  BP          Negative regulation of transcription, DNA-templated           1.55E-03   CC          Nucleus                                  2.34E-04
  BP          Negative regulation of apoptotic process                      1.88E-03   CC          Cytoplasm                                2.69E-04
  BP          Nucleosome assembly                                           3.86E-03   KEGG        Glutathione metabolism                   1.09E-03
  BP          Glutathione derivative biosynthetic process                   4.18E-03   KEGG        Systemic lupus erythematosus             1.93E-03

Discussion {#s4}
==========

Identifying epigenetic patterns is important to understand epigenetic mechanisms in various cancers. The detected patterns among different cancers could demonstrate critical cross-cancer similarities, which reveals some consistent clinical risk among different cancer types and further suggests strong clinical relevance. Our knowledge about the patterns of epigenetic modifications and the cause and consequence of them is still limited. Computational approach that exploits the complex epigenomic landscapes and discovers significant signatures out of them is required. Previous computational methods for analyzing epigenomes primarily focus on the combinatorial states of different epigenetic marks in a specific cell type. Differently, we developed a tri-clustering approach TriPCE for integrative pan-cancer epigenomic analysis. Based on the FP-tree structure, TriPCE can compactly represent all similar cancer types in the promoter regions for a specific epigenetic mark. Using the constructed FP-tree, the frequent patterns are then detected to yield the set of bi-Clusters of this epigenetic mark, indicating the similar epigenetic pattern in these cancer types along these genomic regions. TriPCE further mines the final tri-Clusters based on the bi-Clusters of all investigated epigenetic marks, explicitly detecting combinatorial epigenetic states in different genomic segments and similar epigenetic changes across different cancer types. In the proposed approach TriPCE, the tri-Cluster enumeration is an expensive operation. In the future we plan to develop heuristic techniques to efficiently prune the search space, and then improve the efficiency of mining the tri-Clusters. We applied TriPCE to uncover the similar patterns of six epigenetic marks among seven cancer types and successfully identified significant cross-cancer epigenetic modification similarities, which suggests that there exhibits consistent epigenetic modification tendency among these investigated cancer types. Furthermore, the gene functional analysis demonstrates that these associated genes are strongly relevant with the cancer cellular pathway.
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